Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat

CAMBRIDGE, Mass., Sept. 28, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has resubmitted its New Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news